INT41
Huntington's Disease
Pre-clinicalActive
Key Facts
About Vybion
Vybion is a private, preclinical-stage biotech focused on a novel intrabody platform for neurodegenerative diseases. The company's core technology involves engineering scFv antibody fragments that can be delivered inside cells using AAV or exosomal vectors to interfere with intracellular pathogenic mechanisms. With Orphan Drug Designation for its lead candidate INT41 in Huntington's disease and a pre-IND meeting completed, Vybion is advancing towards clinical development. The leadership team combines deep experience in biologics development, gene therapy, regulatory strategy, and corporate finance.
View full company profileTherapeutic Areas
Other Huntington's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| Huntington's Disease Program | Rumi Scientific | Pre-clinical |
| SOM3355 | SOM Biotech | Phase 3 |
| LETI-101 | ElevateBio | Preclinical |
| Somatic Expansion Inhibitor Program | LoQus23 Therapeutics | Preclinical |
| Preclinical Program | Excision BioTherapeutics | Preclinical |
| NA-841 | Biomed | Phase 2A |
| T3D-959 (Future) | T3D Therapeutics | Pre-clinical / Research |
| HD mAb Therapy | HD Immune | Pre-clinical |
| TT-P34 | Teitur Trophics | Pre-clinical |
| Huntington's Program | reMYND | Pre-clinical |
| Pridopidine | Prilenia Therapeutics | Phase 3 |